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Invasive non-typhoidal salmonella disease: an emerging and 
neglected tropical disease in Africa
Nicholas A Feasey, Gordon Dougan, Robert A Kingsley, Robert S Heyderman, Melita A Gordon
Invasive strains of non-typhoidal salmonellae have emerged as a prominent cause of bloodstream infection in African 
adults and children, with an associated case fatality of 20–25%. The clinical presentation of invasive non-typhoidal 
salmonella disease in Africa is diverse: fever, hepatosplenomegaly, and respiratory symptoms are common, and 
features of enterocolitis are often absent. The most important risk factors are HIV infection in adults, and malaria, 
HIV, and malnutrition in children. A distinct genotype of Salmonella enterica var Typhimurium, ST313, has emerged 
as a new pathogenic clade in sub-Saharan Africa, and might have adapted to cause invasive disease in human beings. 
Multidrug-resistant ST313 has caused epidemics in several African countries, and has driven the use of expensive 
antimicrobial drugs in the poorest health services in the world. Studies of systemic cellular and humoral immune 
responses in adults infected with HIV have revealed key host immune defects contributing to invasive non-typhoidal 
salmonella disease. This emerging pathogen might therefore have adapted to occupy an ecological and immunological 
niche provided by HIV, malaria, and malnutrition in Africa. A good understanding of the epidemiology of this 
neglected disease will open new avenues for development and implementation of vaccine and public health strategies 
to prevent infections and interrupt transmission.
Introduction
The bacterial genus Salmonella causes a huge global 
burden of morbidity and mortality. With regard to human 
disease, salmonellae are divided into typhoidal serotypes 
(Salmonella enterica var Typhi [S Typhi] and Salmonella 
enterica var  Paratyphi A [S Paratyphi A]) and thousands 
of non-typhoidal salmonella serotypes (frequently refer-
red to as NTS serotypes; panel). In high-income coun-
tries, non-typhoidal salmonellae predominantly cause a 
self-limiting diarrhoeal illness in healthy individuals; 
bloodstream or focal infection is rare1 and mainly 
happens in individuals with speciﬁ c risk factors.2 By 
contrast, in sub-Saharan Africa, non-typhoidal sal-
monellae are consistently the most common bacterial 
bloodstream isolates in both adults and children 
presenting with fever,3–7 and are associated with a case 
fatality of 20–25%. Evidence from epidemiological 
studies; whole-genome sequencing of the pathogen; and 
discoveries about host immunity at the cellular, humoral, 
and mucosal level are helping to create a coherent picture 
of an emerging pathogen with a new pathogenesis. We 
will set these new ﬁ ndings in the context of what is 
known from other presentations of salmonella disease, 
and will discuss the similarities to and contrasts with 
typhoid fever.
Historical perspective
Salmonellae were ﬁ rst identiﬁ ed in the late 19th century 
by the US Bureau of Animal Industry.8 Because a broad 
vertebrate host range exists, most salmonella diarrhoeal 
disease in developed countries is still zoonotic. Trans-
mission is increasingly driven by commercial indus-
trial production of meat, eggs, and processed food 
(eg, chocolate,9 jalapeño peppers,10 and peanut butter11).
Non-typhoidal salmonellae were described as a 
common cause of paediatric bloodstream infection in 
Africa in several reports that predate the HIV epidemic,12 
and invasive non-typhoidal salmonellae were ﬁ rst noted 
in children with malaria in 1987.13 In 1983, shortly 
after AIDS was described, two cases of African adults 
with AIDS and Salmonella enterica var Typhimurium 
(S Typhimurium) bacteraemia were reported in 
Belgium.14,15 In 1984, AIDS was identiﬁ ed in Africa (in 
Democratic Republic of the Congo and Rwanda), and 
these reports also included cases of invasive non-typhoidal 
salmonella disease.16,17 The ﬁ rst case series of non-
typhoidal salmonella bacteraemia was described in US 
patients with AIDS in 1984,18 and the ﬁ rst epidemiological 
link between invasive salmonella infection and AIDS was 
made in New Jersey.19 An age-stratiﬁ ed study in New York 
City then showed that invasive non-typhoidal salmonella 
infections were over-represented in registered patients 
with AIDS by a factor of 198, and in patients with 
multiple-site infections by a factor of 305.20 Recurrent 
non-typhoidal salmonella bacteraemia was added to the 
US Centers for Disease Control and Prevention case 
Search strategy and selection criteria
We searched Medline, PubMed, Embase, and the Cochrane 
Library to identify studies published between 2000 and 
2011 about risk factors for, and epidemiology, pathogenesis, 
and treatment of, invasive salmonellae. Our search terms 
were “salmonella” in combination with “typhi”, 
“nontyphoidal”, or “Africa”. We did not limit our search by 
language. We mainly selected articles published in the past 
10 years, but did not exclude important older reports. We 
also searched the reference lists of articles identiﬁ ed by this 
search strategy. Selection criteria included a judgment 
about importance of studies and their relevance for the well 
informed general clinician. We cite review articles where 
they provided comprehensive overviews beyond the scope 
of our Review.
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deﬁ nition for AIDS in 1987. By 1990, non-typhoidal sal-
monella had been conﬁ rmed as a common HIV-related 
pathogen in sub-Saharan African adults.6
By contrast, the typhoidal serotypes S Typhi and 
S Paratyphi A are entirely host restricted to people and 
cause invasive disease in immunocompetent hosts. 
Although once a substantial public health problem in 
developed countries, improvements in sanitation have 
led to near eradication, and most cases are imported. 
A large burden of disease remains in developing 
countries, particularly in Asia. Typhoid fever (also known 
as enteric fever) is an invasive, systemic clinical syndrome 
that is typiﬁ ed by high fever and complicated by sepsis 
and shock, gastrointestinal bleeding or perforation, 
encephalopathy, and focal metastatic complications such 
as cholecystitis or hepatitis. The untreated case fatality is 
20%,21 but is less than 1% with appropriate antimicrobial 
treatment.22 S Typhi persist in the reticuloendothelial 
system and biliary tract, from where bacteria are 
intermittently shed into the gastrointestinal tract, which 
leads to transmission of the disease to other people, 
potentially over many years. Persistence of S Typhi in the 
biliary tract is associated with an increased incidence of 
gallbladder carcinoma in endemic regions.23,24
Burden of disease and epidemiology
Studies of bacteraemia have suggested that invasive non-
typhoidal salmonellae are among the most common 
isolates from febrile presentations in adults and chil dren 
across sub-Saharan Africa, especially where HIV preva-
lence is high (ﬁ gure 1).3 The patchy availability of high-
quality or aﬀ ordable diagnostic microbiology facil ities 
throughout Africa makes accurate documentation of the 
inci dence of invasive non-typhoidal salmonella diﬃ  cult.25 
Under appreciation of disease burden because of in-
adequate diagnostics and reporting is common in a range 
of neglected tropical diseases.26,27 The total burden of 
invasive disease attributable to invasive non-typhoidal 
salmonella in Africa has not been measured but is 
probably substantial, with an estimated annual incidence 
of 175–388 cases per 100 000 children aged 3–5 years,7,28,29 
and 2000–7500 cases per 100 000 HIV-infected adults.3,4,30,31 
A pronounced bimodal age distribution of invasive non-
typhoidal salmonella disease exists in Africa, in which 
children aged 6–36 months32,33 and adults in their third or 
fourth decade are at greatest risk.34 Most cases of invasive 
non-typhoidal salmonella disease across Africa are due 
to either S Typhimurium or Salmonella enterica var 
Enteritidis (S Enteritidis),3,4,13 although investigators at 
some sites report contributions from other serotypes such 
as Salmonella enterica var Isangi (S Isangi) in South 
Africa,35 Salmonella enterica var Concord (S Concord) in 
Ethiopia,36 and Salmonella enterica var Stanleyville (S 
Stanleyville) and Salmonella enterica var Dublin (S 
Dublin)37 in Mali. Researchers at several sites have noted a 
decline in the incidence of invasive non-typhoidal 
salmonella disease, and some have noted a temporal 
association with decreases in malaria infections,38,39 
although this association is not universally reported 
(unpublished).
Although the incidence of invasive non-typhoidal 
salmonella disease is underestimated, the incidence of 
typhoid fever in Africa has perhaps been overestimated. 
However, few population-based data are available. A 
survey of the worldwide burden of typhoid estimated a 
crude incidence in Africa of 50 cases per 100 000 people 
per year,40 but this estimate was based on blood-culture 
data from vaccine trials41,42 from Egypt and South Africa 
in the 1970s and 1980s and could have been inﬂ ated by 
outbreaks or pockets of disease. A review and a meta-
analysis of blood-culture studies3,43 suggest that the 
overall burden of S Typhi is lower than was previously 
estimated in sub-Saharan Africa. S Typhi is, however, the 
predominant invasive salmonella serotype in north 
Africa (where HIV is less prevalent),3 and important foci 
or outbreaks of S Typhi infection remain at some sites in 
sub-Saharan Africa.44–46 The investigators of two studies3,44 
have reported that HIV might be protective against 
typhoid fever.3,44
By contrast with the ﬁ ndings in Africa, a multicentre 
fever surveillance report in Asia identiﬁ ed very little 
invasive non-typhoidal salmonella disease47 compared 
with the dominance of typhoid fever,48 although sampling 
of the youngest (and therefore most at risk) children was 
not done at some study sites. The explanation for such 
disparity between Africa and Asia is unclear, although 
the lower prevalences of Plasmodium falciparum malaria 
and HIV in Asia could be relevant. This pattern might 
change if HIV becomes more prevalent in Asia.49 Reports 
from developed countries in the pre-antiretroviral 
Panel: Salmonella nomenclature
The genus Salmonella consists of rod-shaped, Gram-negative, 
ﬂ agellated facultative anaerobes, and belongs to the family 
Enterobacteriaceae. Two species exist, Salmonella enterica and 
Salmonella bongori; all medically important salmonellae are 
included in the former, and are divided into more than 
2500 serotypes on the basis of surface antigens, by use of a 
scheme initially devised by Kauﬀ man. Serotypes have 
traditionally been named either for the syndrome they were 
thought to cause (eg, Salmonella enterica var Typhimurium 
[S Typhimurium] was thought to cause a typhoid-like 
syndrome in mice) or for the location of their discovery 
(eg, Salmonella enterica var Panama [S Panama]).
Salmonellae causing human disease are traditionally divided 
into a small number of human-restricted invasive typhoidal 
serotypes (eg, Salmonella enterica var Typhi [S Typhi] and 
Salmonella enterica var Paratyphi A [S Paratyphi A]) and 
thousands of non-typhoidal salmonella serotypes 
[commonly known as NTS serotypes]), which typically have a 
broad vertebrate host range and cause various presentations 
that usually include diarrhoeal disease.
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therapy era estimated annual incidences of non-
typhoidal salmonella infections of roughly 400 cases per 
100 000 patients with AIDS, greatly in excess of the rate 
in the general population.20,50 However, some evidence 
shows that the incidence fell after the introduction of 
antiretroviral therapy.50
The contribution of non-typhoidal salmonellae to 
diarrhoeal illness in sub-Saharan Africa is poorly 
described and published work suggests a confusing 
situation. Culture-based studies of diarrhoea in sub-
Saharan Africa have shown that non-typhoidal sal-
monellae are isolated in 2–27% of culture-positive 
diarrhoeal illness,51–53 but are also in the stools of 2–7% of 
asymptomatic controls. Thus, to attribute illness to stool 
positivity is diﬃ  cult. A seroprevalence study of healthy 
children in Malawi revealed that they all had anti-
Salmonella IgG antibodies by the age of 16 months, which 
suggests that infants have been universally exposed to 
either non-typhoidal salmonellae or cross-reactive anti-
gens at a young age.32 A 2010 study of worldwide burden 
of non-typhoidal gastroenteritis estimated 2·5 million 
cases of the disease and 4100 deaths per year in Africa.54 
However, these data were extrapolated from returning 
travellers, who are unlikely to be representative of rural or 
low-income Africans.
We do not know whether the same strains of 
non-typhoidal salmonella cause both invasive and 
diarrhoeal disease, or if not, whether the modes of 
transmission are the same. Basic questions about the 
environmental reservoirs and host ranges of invasive 
strains in Africa remain unanswered. Studies of food 
quality have identiﬁ ed non-typhoidal salmonellae in 
home-cooked food,55 ﬁ sh from the great lakes of Africa, 
and market food,56 but typing beyond serotype or genus 
level was not done and the relevance to invasive disease 
is uncertain. An investigation into the households 
of index cases of paediatric invasive non-typhoidal 
salmonella disease in Kenya showed that 6·9% of human 
contacts carried non-typhoidal salmonellae in their 
stools, and 66% of isolates were similar to the invasive 
strain in the index patient by molecular analysis.57 By 
contrast, only unrelated strains of S Typhimurium, 
S Enteritidis, Salmonella enterica var Agona (S Agona), 
Salmonella enterica var Choleraesuis (S Choleraesuis), 
Salmonella enterica var Derby (S Derby), and Salmonella 
enterica var Anatum (S Anatum) were isolated from 
livestock or the household environment, which raises the 
possibility that transmission is mainly between people. A 
comprehensive investigation into the epidemiology of 
invasive and non-invasive non-typhoidal salmonella 
strains in Africa is urgently needed,25 and data from the 
Global Enterics Multicentre Study could further clarify 
these issues in the near future.
Published accounts of invasive non-typhoidal salmon-
ella in Africa show that the disease is highly seasonal.4 
Peaks of infection during the rainy season in both adults 
and children coincide with increased incidences of 
malaria and malnutrition. Invasive non-typhoidal sal-
monella disease has also been present in epidemics that 
last several years and are caused by sequential single 
serotypes among adults and children. These epidemics 
have been linked to the emergence of resistance to 
commonly used antimicrobial drugs.4
Clinical features in high-income countries
In high-income countries, non-typhoidal salmonellae 
mainly cause a self-limiting enterocolitis in immuno-
competent individuals, in which patients present 
with nausea, vomiting, profuse watery diarrhoea, and 
abdominal pain.58 Up to 5% of patients will develop 
secondary bacteraemia,58–61 but attributable mortality is 
probably low (1–5%). Non-typhoidal salmonellae can 
persist in the gastrointestinal tract after diarrhoeal 
illness, and this risk is increased by antimicrobial 
therapy.62 So-called primary non-typhoidal salmonella 
bacteraemia, without associated diarrhoea, occurs in at-
risk groups—such as patients who are immuno-
suppressed because of HIV infection, steroid use, 
malignancy, chronic renal or liver disease, diabetes, or 
sickle-cell disease, and elderly and newborn patients.2 
Mortality in adults was 12·2% in a hospitalised case 
series in Spain.63 Focal or metastatic disease also 
happens in patients with structural abnormalities, such 
North Africa
Two studies covering 14 locations
10 230 patients, 10·3% with BSI
HIV was not reported
All studies were primarily in adults
Three commonest isolates: Salmonella 49·9% 
(Salmonella enterica var Typhi 99·0%), 
Brucella spp 26·8%, Staphylococcus aureus 7·7%
East Africa
Seven studies covering nine locations
21 317 patients, 7·9% with BSI
18·6% of included patients tested for HIV
23·7% of 3445 tested were seropositive 
for HIV-1
Four studies were primarily in children 
and four were primarily in adults
Three commonest isolates: 
Streptococcus pneumoniae 21·2%, 
Salmonella 17·8% (non-typhoidal 88·0%), 
Escherichia coli 9·5%
Southern Africa
Seven studies covering ﬁve locations
23 893 patients, 9·8% with BSI
5·0% of included patients tested for HIV
59·8% of 1204 tested were seropositive for HIV-1 
Four studies were primarily in children and three were 
primarily in adults
Three commonest isolates: Salmonella 29·0% 
(non-typhoidal 97·0%), S pneumoniae 24·0%, 
S aureus 9·4%
West and central Africa
Six studies covering ﬁve locations
5887 patients, 12·4% with BSI
5·4% of included patients tested
for HIV
63·3% of 319 tested were 
seropositive for HIV-1 or HIV-2
Five studies were primarily in 
children and one was primarily in 
adults
Three commonest isolates: Salmonella 
20·8% (non-typhoidal 87·0%), 
S pneumoniae 18·9%, S aureus 17·2%
Figure 1: Map of Africa showing results of a meta-analysis of studies investigating the cause of bloodstream 
infection in febrile adults and children in Africa
Reproduced from Reddy and colleagues.3 BSI=bloodstream infection. 
For the Global Enterics 
Multicentre Study see http://
medschool.umaryland.edu/
GEMS/default.asp
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as valvular heart disease, aneurysms or atherosclerosis, 
biliary or urinary tract abnormalities, bony abnormalities, 
or prostheses.64
Invasive non-typhoidal salmonella disease can be a 
compli cation of several inherited immunodeﬁ ciencies—
eg, chronic granulomatous disease,65 in which phagocytes 
are unable to kill ingested organisms; sickle-cell disease, 
in which dysfunctional macrophages might cause 
susceptibility; and B-cell deﬁ ciencies.66 Notably, children 
with rare inherited deﬁ ciencies of components of 
the interleukin 12–interleukin 23 pathway have a par-
ticularly high incidence of recurrent invasive non-
typhoidal salmonella infections,67 in keeping with the 
importance of these proinﬂ ammatory cytokines in the 
clearance of intracellular infections.
Clinical features of invasive disease in 
sub-Saharan Africa
The clinical presentation of invasive non-typhoidal sal-
monella disease in Africa is typically febrile systemic 
illness68–70 resembling enteric fever; diarrhoea is often 
absent and other clinical features are diverse and non-
speciﬁ c (ﬁ gure 2).68 A study of bacteraemia in adults in 
Malawi69 noted that a combination of high fever and 
splenomegaly suggested invasive disease, but that 
diag nosis cannot reliably be made without micro bio-
logical tests. In young children especially, a problematic 
clinical overlap exists with the presentations of 
pneumonia and malaria,70–72 and paediatric guidelines 
for empirical diagnosis and treatment in low-income 
settings fail to identify or treat invasive non-typhoidal 
salmonella disease. Patients with invasive disease 
frequently present with apparent focal infection, 
particu larly of the lower respiratory tract, which is 
commonly attributable to co-infection with other 
pathogens such as Mycobacterium tuberculosis73 and 
Streptococcus pneumoniae.68 Even micro biologically 
conﬁ rmed invasive non-typhoidal salmonella disease 
treated with appropriate antimicrobial drugs has a case 
fatality of 22–47% in African adults and children.4,68
Risk factors for invasive non-typhoidal salmonella 
disease in children include HIV infection; malnutrition;70 
and malaria, especially severe malarial anaemia,13,74 acute 
severe malaria,75 and recent malaria.76 Sickle-cell anaemia 
is also an important risk factor in African children.77 
Invasive non-typhoidal salmonella predates HIV as an 
important clinical disease in children in Africa13,78–81 and, 
although HIV is independently associated with the illness 
in febrile paediatric admissions (odds ratio 2·6), only 
roughly 20% of African children who get non-typhoidal 
salmonella disease are infected with HIV.4,76 The main risk 
factor in adults is undoubtedly advanced HIV infection. 
Case series typically show 95% of adult cases to be in 
people infected with HIV, of whom 80% have a CD4 
T-lymphocyte count of fewer than 200 cells per μL.68 In 
adults infected with HIV, before the antiretroviral therapy 
era 20–40% of survivors had recurrence,4,68 even after 
appropriate antimicrobial drugs; despite retreatment, up 
to 25% of patients had several recurrences. Genomic 
typing of index and recurrence strains suggests that 
recrudescence is more common than reinfection as a 
cause of recurrences.82
In addition to sepsis, invasive non-typhoidal salmonella 
can seed to the meninges, especially in children. In 
Malawi, S Typhimurium has been the second most 
common cause of bacterial meningitis since the intro-
duction of the Haemophilus inﬂ uenzae B vaccine, and 
accounted for 15% of culture-proven meningitis in 
2008 (unpublished). The case fatality of salmonella 
meningitis is 52% in children and 80% in adults.83 
Additionally, invasive non-typhoidal salmonella infection 
in African children is associated with active schisto-
somiasis,84–88 because the bacteria can adhere to the adult 
helminth’s tegument,89,90 where they can evade anti micro-
bial treatment. Treatment with praziquantel kills the 
adult helminth and allows antibacterial drugs to eradicate 
the bacteria. Schistosomiasis has not been shown to 
contribute to susceptibility, death, or recurrence of 
invasive non-typhoidal salmonella disease in adults 
infected with HIV.91,92
Management in Africa
Salmonellae were once susceptible to a broad range 
of aﬀ ordable and eﬀ ective antimicrobial drugs, but 
multidrug-resistant strains4,93 have emerged in Africa. 
In Malawi, epidemics of multidrug-resistant invasive 
non-typhoidal salmonella (deﬁ ned as resistant to 
ampicillin, chloramphenicol, and co-trimoxazole) have 
been recorded.4 S Typhimurium was shown to contain a 
composite element encoding multidrug-resistant genes 
located on a virulence-associated plasmid (pSLT-BT), thus 
potentially linking resistance to antimicrobial drugs with 
virulence.93 Resistance has necessitated the widespread 
use of expensive drugs for empirical management of 
sepsis, such as third generation cephalosporins and 
Fever: 95% of cases, no
apparent focus in 35%
Blood tests: Severe anaemia in 40–50%
of adults and 25–40% of children,
95% of adults and 20% of children are
HIV positive, CD4 count <200 cells
per μL in 80% of adults
Splenomegaly: 30–45% of cases
Hepatomegaly: 15–35% of cases
Diarrhoea: 20–50% of cases, but
often not a prominent feature
Pneumonia: 60% of children
and 30% of adults have an
apparent lower respiratory
tract infection focus, commonly
due to co-infection
Figure 2: Clinical features of invasive non-typhoidal salmonella disease in adults and children in Africa
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ﬂ uoroquinolones (eg, ciproﬂ oxacin), which the poorest 
health systems in the world can ill aﬀ ord, and which 
could promote the development of further resistance.
No intervention studies have been done to inform the 
best combined antimicrobial and antiretroviral therapy 
regimen to treat acute infection and prevent relapse. 
Infectious Disease Society of America guidelines for 
the management of invasive non-typhoidal salmonella 
disease in HIV-infected adults recommend 2–6 weeks of 
ﬂ uoro quinolone therapy.94 Fluoroquinolones, however, are 
also important in the management of drug-resistant tuber-
culosis, and since the two organisms can co-infect HIV-
positive patients,73 further tuberculosis resistance could be 
promoted. Our experience is that rapid com mence ment of 
antiretroviral therapy can prevent relapse and therefore 
avert recurrent ﬂ uoro quinolone exposures (unpublished). 
Azithromycin is an attractive alternative antimicrobial 
drug. Ceftriaxone is probably an appropriate ﬁ rst-line 
intravenous treatment for patients unable to take oral 
drugs, but aminoglycosides do not penetrate intracellularly 
and are therefore not appropriate for treatment.
Recurrent invasive non-typhoidal salmonella disease, 
in the context of HIV, declines after antiretroviral 
therapy is started.95 The rollout of antiretroviral therapy 
will probably reduce the incidence of invasive illness 
in Africa.50
Pathogenesis in immunocompetent hosts
In immunocompetent hosts, most clinical isolates of 
non-typhoidal salmonella cause inﬂ ammatory entero-
colitis and diarrhoea, and can infect a broad range of 
potential vertebrate hosts. By contrast, typhoidal strains 
evade the gut mucosal immune response to cause 
systemic disease in a manner that is restricted to human 
beings and possibly analogous to the clinical picture 
noted in invasive non-typhoidal salmonella in Africa. 
Much progress has been made in understanding the 
mechanisms underlying the range of clinical syndromes 
reported, and their relevance to the host range and 
transmission of diﬀ erent serotypes (ﬁ gure 3).
In relation to diarrhoeal disease, non-typhoidal 
salmonella can exploit the gut mucosal inﬂ ammatory 
response that accompanies infection in immuno-
competent individuals to gain a selective advantage over 
the resident gut microbiota in the inﬂ amed gut lumen.96 
Many mechanisms probably underpin this mode of 
pathogenesis. For example most salmonellae harbour an 
iro gene cluster (iroN, iroBCDE), which can confer 
resistance to the host antimicrobial peptide lipocalin 2 by 
encoding a lipocalin-resistant siderophore that supplies 
iron in the inﬂ amed gut.97 Salmonellae are also equipped 
to metabolically out-compete the microbiota in an 
inﬂ ammatory environment. For example, they can 
stimulate host-driven production of an electron acceptor 
that allows the pathogen to use respiration to compete 
with fermenting gut microbes.98 Thus, the symptoms of 
non-typhoidal salmonella diarrhoeal gastroenteritis are 
caused by inﬂ ammatory mechanisms that are also key to 
transmission of the luminal pathogen.
S Typhi, by contrast, generally avoid triggering a 
dominant primary gut mucosal inﬂ ammatory response 
through evasion mechanisms with virulence-associated 
adaptations such as the expression of the immuno-
modulatory Vi capsule and the accumulation of an 
inactivated gene repertoire that might favour entry 
through a non-inﬂ ammatory pathway. S Typhi also 
target small intestinal microfold cells, which are 
epithelial cells overlying Peyer’s patches that sample the 
antigenic content of the gut.99 These cells direct S Typhi 
to underlying phagocytes such as dendritic cells and 
macrophages in the lamina propria, which favour 
intracellular dis semination to the lymphatics, the 
bloodstream, and viscera.100,101 The bacteria persist in the 
reticuloendothelial system where they replicate before 
they are shed back into the circulation (precipitating 
symptoms of enteric fever) and into the gastrointestinal 
tract in infected bile. This alternative invasive strategy of 
typhoidal salmonellae ensures a long period of shedding 
by a small number of individuals and thus secures the 
onward transmission of this human-restricted organism.
Invasive non-typhoidal salmonella disease in 
HIV-positive adults
Three key immunological defects have been described 
that could contribute to the invasive pathogenesis of 
non-typhoidal salmonella in HIV-infected adults in Africa 
(ﬁ gure 4). First, an important defect has been identiﬁ ed in 
the gut mucosa. The gastrointestinal tract is a site of early 
Generalists
Enteric/diarrhoeal disease
Low mortality
Invasive/systemic disease
High mortality
•  Diverse genomic repertoire
    supporting broad host range
•  Genome degradation of so-called
“generalist” genes
•  Specific additional virulence genes
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Figure 3: Features of host adaptation in salmonellae and eﬀ ects on clinical syndrome in the host
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and profound CD4 T-cell depletion in HIV infection,102 
especially interleukin-17-producing T cells (Th17 cells). 
Th17 cells and their associated family of cytokines, 
including interleukins 17, 21, 22, and 26, coordinate 
mucosal defence through several mecha nisms. They are 
crucial to the integrity, repair, and maintenance of the 
epithelial mucosal barrier, and induce epithelial cell 
expression of antimicrobial peptides such as β defensins 
and lipocalin. Additionally, Th17 cells have an important 
role in the stimulation of innate immune responses, by 
mediating neutrophil chemo attraction and function.103
A study in macaques positive for the simian immuno-
deﬁ ciency virus, which used a ligated ileal loop model, 
showed that infected animals had depleted interleukin-
17-producing mucosal cells, blunted cellular Th17 
responses, and reduced expression of genes implicated 
in the maintenance of the epithelial barrier.104 Bacterial 
trans location across the gut mucosa and systemic 
dissem ination of salmonellae also took place. A key role 
for Th17 responses in protection against Salmonella 
dissemination was conﬁ rmed by use of a streptomycin-
pretreated mouse model deﬁ cient in interleukin 
17 receptors, which also showed reduced neutrophil 
inﬂ ux and increased S Typhimurium invasion.104 These 
data show that loss of gut mucosal interleukin 17 cells in 
HIV infection is probably a key mechanism by which 
salmonellae disseminate from the gut to cause invasive 
disease in these patients. Loss of neutrophil chemo-
attraction could also explain the apparent absence of 
enteritis and diarrhoeal disease during HIV-associated 
invasive non-typhoidal salmonella.68
Second, dysregulated cytokine production during 
intracellular infection seems to allow persistence and 
recurrence of invasive non-typhoidal salmonella. Intra-
cellular replication and persistence are key pathogenic 
competencies for salmonellae causing invasive disease. 
Quantitative blood cultures and bone-marrow cultures 
taken from HIV-positive adults with invasive non-
typhoidal salmonella revealed a similar quantity of 
bacteria in both compartments at ﬁ rst presentation, but a 
six-times greater concentration of salmonellae in bone 
marrow compared with blood during relapse, which 
suggests persistence and replication. Further more, a 
substantial proportion of bacteria both in blood and bone 
marrow were in the intracellular compartment during 
invasive non-typhoidal salmonella infection. Bacterial 
load at relapse negatively correlated with cytokine con-
centrations and CD4 cell count, which suggests that 
failure of immunological control permitted escape from 
the intracellular compartment and symptomatic relapse.105
Investigation of intracellular killing and cytokine 
production by ex-vivo macrophages from HIV-infected 
adults did not show an intrinsic defect of macrophage 
killing, but instead demonstrated a highly dysregulated 
cytokine environment after S Typhimurium challenge. 
Tumour necrosis factor α, interleukin 10, and interleukin 
12 were produced in excess during early HIV disease, but 
substantially reduced in late HIV disease, when adults 
infected with HIV are most susceptible to invasive non-
typhoidal salmonella disease.106 Pronounced attenuation 
of proinﬂ ammatory cytokine responses is conﬁ rmed by 
transcriptional analysis of whole-blood responses.107 
Cytokine responses are crucial for control of intracellular 
Salmonella infection,108 and the dysregulation and 
attenuation reported in HIV infection probably explain 
intra cellular persistence of the bacteria, failure of 
immuno logical control, and episodes of relapse of 
invasive non-typhoidal salmonella disease recorded in 
advanced HIV infection.
Finally, the importance of antibodies both for serum 
killing and intracellular oxidative killing of invasive 
salmonella is increasingly recognised.32,108,109 A new 
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1)  Loss of interleukin 17-producing CD4 T cells from the 
gut mucosa in HIV leads to:
• failure to maintain the epithelial cell barrier
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3)  Humoral defect in HIV
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Figure 4: Three key defects that contribute to the pathogenesis of invasive non-typhoidal salmonellae in 
HIV-positive people
Arrows show routes of dissemination of salmonellae.
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humoral defect has been described in Malawian adults 
infected with HIV, a proportion of whom had impaired 
serum killing of non-typhoidal salmonella strains. 
Paradoxically, this impairment was associated with the 
presence, rather than absence of IgG antibodies directed 
against Salmonella. The antibodies, directed against 
Salmonella lipopolysaccharide, were shown to impair 
serum killing by blocking or competing with co-
existing eﬀ ective bactericidal antibodies directed against 
Salmonella outer membrane proteins.110 Although the 
clinical importance of these antibodies is still not proven in 
terms of a relation with disease susceptibility or outcomes 
in patients, this ﬁ nding could have some implications for 
the choice of targets for potential vaccines.
Immunological defects in African children
In children, other disorders are more important risk 
factors for invasive non-typhoidal salmonella than is 
HIV infection, especially severe malarial anaemia and 
malnutrition. The mechanism through which malaria 
predisposed to invasive non-typhoidal salmonella was 
thought to be mainly macrophage dysfunction as a result 
of iron release after haemolysis, but work in mice suggests 
a more complex interplay between the bacteria and malaria 
that involves both cytokine dysregulation111 and haem 
oxygenase-dependent dysfunc tional granulo cyte mobil-
isation.112 Although homozygosity for sickle-cell anaemia is 
a risk factor for invasive non-typhoidal salmonella,77 
heterozygosity is protective against bacter aemias, probably 
because of the strong protection aﬀ orded against malaria.38 
By contrast with the situation described in HIV-infected 
adults, African children aged 4–16 months have poor 
serum killing of Salmonella associated with an early 
deﬁ ciency of anti-Salmonella IgG and an excess of invasive 
non-typhoidal salmonella.32 Furthermore, invasive non-
typhoidal salmonella infec tion is less common in the ﬁ rst 
3–4 months of life than in later childhood, consistent with 
temporary protec tion aﬀ orded by transplacental protective 
antibodies, anti bodies in maternal colostrum, or avoidance 
of environmental exposure during exclusive breastfeeding. 
Together, these ﬁ ndings suggest that antibodies play an 
important part in protection against invasive non-typhoidal 
salmonella in children.
Evolution and host adaptation of 
S Typhimurium in Africa
To understand the pathogenesis of invasive non-
typhoidal salmonella disease, both human-host immun-
ity and the sub stantial genetic diversity of the genus 
Salmonella must be considered. Host-restricted sal-
monellae such as S Typhi, which are traditionally 
associated with systemic disease, have evolved a more 
restricted genomic repertoire, whereas salmonellae that 
maintain a broad host range predominantly cause 
enteritis (ﬁ gure 3). The loss of functional gene capacity 
in invasive serotypes such as S Typhi and S Paratyphi A 
is at least partly attributable to the inactivation of genes 
that allow persistence of promiscuous serotypes in the 
intestinal lumen and the ability to target and manipulate 
host cells.113,114 Loss of functional gene capacity with 
genome degradation from a progenitor with a broad host 
range has been reported in other human-restricted 
pathogens such as Mycobacterium leprae,115 Yersinia 
pestis,116 Bordetella pertussis,117 and Rickettsia spp.118
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Figure 5: Radial phylogram showing the phylogenetic relations of Salmonella enterica var Typhimurium 
(S Typhimurium) sequence types (STs)
The S Typhimurium sequence types (red or yellow circles) are rooted to Salmonella enterica var Typhi (S Typhi) 
(blue circle) and Salmonella enterica var Paratyphi A (S Paratyphi A) (green circle). Genetic distance is calculated as 
the number of single nucleotide polymorphisms per base and is indicated as a solid black line. The length of this 
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The Salmonella serotypes that most commonly 
cause invasive non-typhoidal salmonella in Africa are 
S Typhimurium and S Enteritidis, which are usually 
associated with a broad host range and with enteric 
disease.119 Whole-genome sequencing and PCR analysis 
done on a series of invasive isolates of S Typhimurium 
from Malawi and Kenya identiﬁ ed a dominant regional 
genotype—multilocus sequence type (ST) 313, which is 
uniquely found in Africa, and which has several genetic 
diﬀ erences compared with other strains of this serotype 
(ﬁ gure 5).93 Although other genotypes of S Typhimurium 
such as ST19 (which includes classic gastrointestinal 
strains such as DT104) can also cause invasive non-
typhoidal salmonella in Africa, ST313 isolates are dominant 
in many sub-Saharan regions. ST313-like isolates from 
central Africa have been retrospectively identiﬁ ed as early 
as the 1980s (Al-Mashhadani M,  Parry CM, University of 
Liverpool, personal communication).
An important characteristic of ST313 isolates is a 
degraded genome capacity in the form of pseudogenes 
and deletions. 60% of this degraded genomic repertoire is 
also degraded in S Typhi and S Paratyphi. Some of these 
genes have known functions relating to patho genesis and 
some are of unknown function, but the convergence 
between ST313 and S Typhi, despite the distinct 
phylogenetic lineages of these Salmonella species120 
(ﬁ gure 5) raises the possibility that ST313 has adapted to 
occupy a unique niche in Africa and undergone con-
vergent microevolution to become human adapted.93
We do not know whether these ST313 strains cause an 
appreciable burden of gastroenteritis in Africa. However, 
Salmonella isolates of an identical type were recovered 
from healthy people cohabiting with index cases of 
invasive non-typhoidal salmonella disease in Kenya, 
which suggests that asymptomatic carriage could be 
important in the transmission of these pathogens.57 
Molecular epidemiological analysis of invasive and 
diarrhoeal strains of S Typhimurium and S Enteritidis 
will be valuable to understand and interrupt the trans-
mission of invasive ST313 strains in Africa. However, the 
immunological and genetic characteristics of the host 
could still be the dominant factor aﬀ ecting susceptibility 
to invasive non-typhoidal salmonella.
Future research priorities
The true burden of salmonella disease in Africa is unclear. 
A comprehensive epidemiological study of invasive non-
typhoidal salmonella, diarrhoeal non-typhoidal sal mon-
ella, and S Typhi that assesses the possible methods of 
transmission is urgently needed. The potential value of 
whole-genome-sequencing technologies has already been 
shown in epidemiological investigations of S Typhi in 
Asia.121 S Typhimurium ST313 might be becoming human 
adapted, and investigation of the reservoirs and risk factors 
for exposure and transmission will provide hypothesis-
driven approaches to preventive measures—eg, vaccines, 
improved hygiene and sanitation, improved nutrition, 
malaria control, and antiretroviral therapy programmes.
Clinical algorithms fail to reliably identify invasive 
non-typhoidal salmonella in adults or children in 
Africa. Blood culture and microbiological diagnosis of 
Salmonella requires technical expertise and investment 
in infra struc ture, consumables, and quality control, all of 
which must be strengthened in the region. An urgent 
need exists for the development of rapid, accurate 
point-of-care diag nostics to supplement conventional 
diagnostic micro biology. Targets for a non-typhoidal 
salmonella rapid multi plexed PCR diagnostic have been 
identiﬁ ed,37 but low numbers of the bacilli in blood make 
this process a technical challenge.104 Similar limitations 
have been noted in typhoid fever.122 A new ultra-fast 
method for detecting the Salmonella ori C chromosomal 
locus shows promise but needs validation and translation 
to real-world application.123
Vaccine development is a potential prospect for non-
typhoidal salmonella control. The few Salmonella enterica 
vaccines so far have targeted S Typhi in people, but several 
approaches could be used to vaccinate against invasive 
disease. Inactivated whole cells have historically provided 
the basis for oral vaccines, such as those for cholera.124 This 
approach would be cheap, but its eﬀ ectiveness against 
invasive disease is unclear. Live oral African non-typhoidal 
salmonella vaccine strains that were attenuated by 
mutations in guanine synthesis and ﬂ agellum regulatory 
genes protected mice against lethal infection with both 
S Typhimurium and S Enteritidis—such strains could be 
used as part of a vaccination strategy.125 A second approach, 
pioneered with the Vi antigen of S Typhi,126 would be to 
target surface polysaccharides (particularly O sidechains) 
in the form of a conjugate vaccine, and some programmes 
are pursuing this strategy. Diﬀ erent non-typhoidal 
salmonella serotypes, however, have immuno logically 
distinct O sidechains, and consequently a multiple-antigen 
vaccine might be needed. A further approach could target 
surface protein antigens such as the porins or ﬂ agella.125,127,128 
Protein antigens can be protective in mice, but this eﬀ ect 
has not yet been translated into human vaccines. Non-
typhoidal vaccine development is also complicated by the 
immuno compromised nature of susceptible patients,108,110 
which should be addressed early in clinical development.
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